RxDoctor Payments Data

Hiren Patel, MD

Pulmonary Disease · Marietta, GANPI 1154579084

Payments from drug & device makers

$24,252in general payments, 2019–2025

Across 304 payments — averaging $79.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$14K
  • Pulmonx Corporation$4K
  • Siemens Medical Solutions USA, Inc.$942
  • GSK$917
  • Grifols USA, LLC$451
  • Boehringer Ingelheim$412
  • plus $4K from 40 others

What the payments were for

  • Speaking & faculty fees$3,13713%
  • Travel & lodging$5,80324%
  • Food & beverage$7,17430%
  • Education$8,13934%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,252 in reported general payments places this provider in the 80th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$91,445
Medicare patients
327
Services billed
868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter183$162,895
Breztri AerosphereBudesonide/Glycopyr/Formoterol82$66,365
Dupixent SyringeDupilumab11$48,280
XolairOmalizumab14$43,175
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$36,473
EliquisApixaban36$34,465
Spiriva RespimatTiotropium Bromide58$29,425
Stiolto RespimatTiotropium Br/Olodaterol Hcl54$25,436
Breo ElliptaFluticasone/Vilanterol55$23,329
Formoterol Fumarate11$11,549
XareltoRivaroxaban12$9,404
Incruse ElliptaUmeclidinium Bromide26$8,192
Bevespi AerosphereGlycopyrrolate/Formoterol Fum19$7,864
SymbicortBudesonide/Formoterol Fumarate32$7,040
Albuterol Sulfate HfaAlbuterol Sulfate207$5,567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$917$230,889317 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$382$81,269133 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$412$54,861112 claims
PfizerEliquis$14$34,46536 claims
Johnson & JohnsonXarelto$335$9,40412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →